BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

844 related articles for article (PubMed ID: 26752111)

  • 1. Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis.
    Koi M; Garcia M; Choi C; Kim HR; Koike J; Hemmi H; Nagasaka T; Okugawa Y; Toiyama Y; Kitajima T; Imaoka H; Kusunoki M; Chen YH; Mukherjee B; Boland CR; Carethers JM
    Gastroenterology; 2016 Apr; 150(4):944-55. PubMed ID: 26752111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q.
    Sarli L; Bottarelli L; Bader G; Iusco D; Pizzi S; Costi R; D'Adda T; Bertolani M; Roncoroni L; Bordi C
    Dis Colon Rectum; 2004 Sep; 47(9):1467-82. PubMed ID: 15486743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping of genetic deletions on chromosome 3 in colorectal cancer: loss of 3p25-pter is associated with distant metastasis and poor survival.
    Tsai MH; Fang WH; Lin SH; Tzeng ST; Huang CS; Yen SJ; Chou SJ; Yang YC
    Ann Surg Oncol; 2011 Sep; 18(9):2662-70. PubMed ID: 21347784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
    Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
    J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
    Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K
    World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers.
    Ogino S; Nosho K; Irahara N; Shima K; Baba Y; Kirkner GJ; Meyerhardt JA; Fuchs CS
    J Clin Oncol; 2009 Sep; 27(27):4591-8. PubMed ID: 19704056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annexin A10 expression in colorectal cancers with emphasis on the serrated neoplasia pathway.
    Bae JM; Kim JH; Rhee YY; Cho NY; Kim TY; Kang GH
    World J Gastroenterol; 2015 Sep; 21(33):9749-57. PubMed ID: 26361422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations.
    Mouradov D; Domingo E; Gibbs P; Jorissen RN; Li S; Soo PY; Lipton L; Desai J; Danielsen HE; Oukrif D; Novelli M; Yau C; Holmes CC; Jones IT; McLaughlin S; Molloy P; Hawkins NJ; Ward R; Midgely R; Kerr D; Tomlinson IP; Sieber OM
    Am J Gastroenterol; 2013 Nov; 108(11):1785-93. PubMed ID: 24042191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Single-organ Metastasis to the Liver or Lung and Genetic Mutation Status on Prognosis in Stage IV Colorectal Cancer.
    Cavallaro P; Bordeianou L; Stafford C; Clark J; Berger D; Cusack J; Kunitake H; Francone T; Ricciardi R
    Clin Colorectal Cancer; 2020 Mar; 19(1):e8-e17. PubMed ID: 31899147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allelic loss of a common microsatellite marker MYCL1: a useful prognostic factor of poor outcomes in colorectal cancer.
    Kambara T; Sharp GB; Nagasaka T; Takeda M; Sasamoto H; Nakagawa H; Isozaki H; MacPhee DG; Jass JR; Tanaka N; Matsubara N
    Clin Cancer Res; 2004 Mar; 10(5):1758-63. PubMed ID: 15014029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma.
    Kakar S; Deng G; Smyrk TC; Cun L; Sahai V; Kim YS
    Mod Pathol; 2012 Jul; 25(7):1040-7. PubMed ID: 22522845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between genetic alterations and prognosis in sporadic colorectal cancer.
    Chang SC; Lin JK; Yang SH; Wang HS; Li AF; Chi CW
    Int J Cancer; 2006 Apr; 118(7):1721-7. PubMed ID: 16231316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
    Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
    Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
    Miranda E; Bianchi P; Destro A; Morenghi E; Malesci A; Santoro A; Laghi L; Roncalli M
    Cancer; 2013 Jan; 119(2):266-76. PubMed ID: 22786759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
    Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
    Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity: an independent prognostic factor of colorectal cancer.
    Chang SC; Lin JK; Lin TC; Liang WY
    World J Gastroenterol; 2005 Feb; 11(6):778-84. PubMed ID: 15682467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of heterozygosity at D8S298 is a predictor for long-term survival of patients with tumor-node-metastasis stage I of hepatocellular carcinoma.
    Pang JZ; Qin LX; Ren N; Hei ZY; Ye QH; Jia WD; Sun BS; Lin GL; Liu DY; Liu YK; Tang ZY
    Clin Cancer Res; 2007 Dec; 13(24):7363-9. PubMed ID: 18094418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
    Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
    J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.